Table 2.
Antibody-drug conjugates at phase III clinical trial
| Name | Target | Payload | Indication(s) | ClinicalTrials.gov identifier |
|---|---|---|---|---|
| Mirvetuximab soravtansine (IMGN853) | Folate receptor α | DM4 | Epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, ovarian cancer | NCT04296890, NCT04209855, NCT02631876 |
| Transtuzumab duocarmazine (SYD985) | HER2 | seco-DUBA | Metastatic breast cancer | NCT03262935 |
| Depatuxizumab mafodotin (ABT-414) | EGFR | MMAF | Glioblastoma, gliosarcoma | NCT02573324, NCT03419403 |
| Disitimab vedotin (RC48-ADC) | HER2 | MMAE | Locally advanced or metastatic breast cancer with low expression of HER2 | NCT04400695 |